Christopher P. Marshall, PhD, CEO. Chris founded the company, is a serial entrepreneur, a former consultant (OliverWyman), and is a licensed patent agent. He received his PhD in biochemistry, with minors in virology & immunology, from the Rockefeller University. He has led the company's efforts to obtain $8.3M in non-dilutive grants and to use these funds to advance the company's technology and asset development to this exciting juncture.

Mark Yondola, PhD, CSO. Mark joined Calder in 2013 after his postdoctoral training with Dr. Peter Palese. He established Calder’s 3D-VaxLock platform technology and developed the cell line, processes & analytics for the clinical manufacture of Calder's RSV vaccine, which are ready for tech transfer to a CDMO. He is the principal investigator of the company's current applications & awards. Mark has served on multiple NIH/DOD review panels.

Dirk Pleimes, MD, CMO. Dirk is expert in clinical research and regulatory; he has run early and late-stage clinical trials as global medical lead at Bayer Healthcare and has founded several biotech companies. Dirk has developed the regulatory & clinical development strategies for Calder's RSV vaccine, and submitted an early briefing to the FDA to obtain regulatory feedback and guidance for our RSV vaccine's preclinical development.

Daniel Catron, COO. Dan is expert in licensing and business development. He has served as Executive Director, Licensing and Business Development at Allele Biotech & Pharmaceuticals, and as Director, technology transfer, at Scripps Research Institute; he received his MBA from the University of Miami. Dan is responsible for managing the company's contracts and external development programs, including two CDMO relationships.